The aim of this study is to explore whether the clinical efficacy of administration of tamoxifen (5 mg/day) for 5 years following BCS is not inferior in reducing recurrence of breast events when compared with RT following BCS in breast DCIS patients with low-risk clinicopathologic features and positive ER status in tumors. Here, ESR1 is linked to ductal breast carcinoma in situ.